{"organizations": [], "uuid": "758929a0626886f6810a65c9b2db5e77aa7f82d9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180524.html", "section_title": "Archive News &amp; Video for Thursday, 24 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/products-fosamax/government-asks-supreme-court-to-take-up-fosamax-preemption-appeal-idUSL2N1SV2EF", "country": "US", "domain_rank": 408, "title": "Government asks Supreme Court to take up Fosamax preemption appeal", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-25T05:22:00.000+03:00", "replies_count": 0, "uuid": "758929a0626886f6810a65c9b2db5e77aa7f82d9"}, "author": "Tina Bellon", "url": "https://www.reuters.com/article/products-fosamax/government-asks-supreme-court-to-take-up-fosamax-preemption-appeal-idUSL2N1SV2EF", "ord_in_thread": 0, "title": "Government asks Supreme Court to take up Fosamax preemption appeal", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "supreme court", "sentiment": "negative"}, {"name": "merck & co", "sentiment": "negative"}, {"name": "u.s. supreme court", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "3rd circuit u.s. court of appeals", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "The U.S. Solicitor General urged the U.S. Supreme Court to take up an appeal by Merck & Co, saying a federal appeals court wrongly decided a case alleging the company failed to warn of risks that its osteoporosis drug Fosamax could cause atypical femur fractures.\nThe 3rd Circuit U.S. Court of Appeals ruled last year that the claims could go before a jury, rejecting Merck’s argument that the they were preempted by the U.S. Food and Drug Administration’s 2009 rejection of a label change warning of the risk.\nTo read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2IJRBQD\n ", "external_links": ["http://bit.ly/2IJRBQD", "https://twitter.com/reuters", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://www.youtube.com/user/ReutersVideo", "https://instagram.com/reuters/"], "published": "2018-05-25T05:22:00.000+03:00", "crawled": "2018-05-25T16:16:46.000+03:00", "highlightTitle": ""}